Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced ER+, HER2-Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT05501769
What this trial is testing

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 32
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Testing effectiveness (Phase 2)Study completedNCT01698918
What this trial is testing

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast Cancer
Novartis Pharmaceuticals 202
Large-scale testing (Phase 3)Study completedNCT02941926
What this trial is testing

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,246
Testing effectiveness (Phase 2)Study completedNCT05054374
What this trial is testing

Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT02018458
What this trial is testing

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

Who this might be right for
Breast Cancer
Baylor Research Institute 10
Testing effectiveness (Phase 2)Looking for participantsNCT07235176
What this trial is testing

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

Who this might be right for
Advanced ER+/HER2- Breast Cancer
Qilu Pharmaceutical Co., Ltd. 300
Early research (Phase 1)Active Not RecruitingNCT04288089
What this trial is testing

H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Who this might be right for
Receptors, EstrogenGenes, Erbb-2Breast Neoplasms
Eisai Inc. 31
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Large-scale testing (Phase 3)Active Not RecruitingNCT04650581
What this trial is testing

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Who this might be right for
Breast Cancer
Canadian Cancer Trials Group 250
Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Testing effectiveness (Phase 2)WithdrawnNCT03644589
What this trial is testing

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Breast Cancer+3 more
University of Washington
Large-scale testing (Phase 3)UnknownNCT04753177
What this trial is testing

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Who this might be right for
The Neoadjuvant Therapy
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary 120
Early research (Phase 1)Active Not RecruitingNCT03616587
What this trial is testing

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 396
Testing effectiveness (Phase 2)Study completedNCT03781063
What this trial is testing

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc. 100
Testing effectiveness (Phase 2)Ended earlyNCT01697293
What this trial is testing

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Who this might be right for
Breast AdenocarcinomaEstrogen Receptor PositiveHER2/Neu Negative+6 more
Prescient Therapeutics, Ltd. 34
Early research (Phase 1)Ended earlyNCT05489679
What this trial is testing

AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 6
Early research (Phase 1)Ended earlyNCT04504331
What this trial is testing

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerER Positive Breast Cancer+1 more
Jennifer Lee Caswell-Jin 4
Testing effectiveness (Phase 2)WithdrawnNCT01361945
What this trial is testing

AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHER-2 Positive Breast Cancer+1 more
Texas Tech University Health Sciences Center, El Paso
Early research (Phase 1)Active Not RecruitingNCT04360941
What this trial is testing

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast Cancer+3 more
Royal Marsden NHS Foundation Trust 45
Next Page